Cargando…

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study

BACKGROUND: The length of time that people with HIV on antiretroviral therapy (ART) with viral load suppression will be able to continue before developing viral rebound is unknown. We aimed to investigate the rate of first viral rebound in people that have achieved initial suppression with ART, to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'Connor, Jemma, Smith, Colette, Lampe, Fiona C, Johnson, Margaret A, Chadwick, David R, Nelson, Mark, Dunn, David, Winston, Alan, Post, Frank A, Sabin, Caroline, Phillips, Andrew N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489695/ https://www.ncbi.nlm.nih.gov/pubmed/28479492 http://dx.doi.org/10.1016/S2352-3018(17)30053-X

Ejemplares similares

Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study
por: O'Connor, Jemma, et al.
Publicado: (2014)

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines
por: El Bouzidi, Kate, et al.
Publicado: (2020)

Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status
por: Lampe, Fiona C.
Publicado: (2016)

Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses
por: Burch, Lisa S, et al.
Publicado: (2016)

Impact on life expectancy of HIV-1 positive individuals of CD4(+) cell count and viral load response to antiretroviral therapy
por: May, Margaret T., et al.
Publicado: (2014)

All-cause hospitalization according to demographic group in people living with HIV in the current antiretroviral therapy era
por: Rein, Sophia M., et al.
Publicado: (2021)

Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014)

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
por: May, Margaret, et al.
Publicado: (2011)

Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study
por: Price, Huw, et al.
Publicado: (2012)

Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK
por: Brima, Nataliya, et al.
Publicado: (2017)

Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) Naïve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission
por: Rodger, Alison J., et al.
Publicado: (2014)

Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
por: Castro, Hannah, et al.
Publicado: (2012)

First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda
por: Castelnuovo, Barbara, et al.
Publicado: (2016)

Non-Disclosure of HIV Status and Associations with Psychological Factors, ART Non-Adherence, and Viral Load Non-Suppression Among People Living with HIV in the UK
por: Daskalopoulou, Marina, et al.
Publicado: (2016)

Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland
por: Duong, Trinh, et al.
Publicado: (2014)

Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure
por: Shroufi, Amir, et al.
Publicado: (2019)

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
por: Geretti, Anna Maria, et al.
Publicado: (2019)

A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada
por: Patterson, S, et al.
Publicado: (2017)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study
por: May, M, et al.
Publicado: (2012)

Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy
por: Tang, Yuyang, et al.
Publicado: (2023)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK
por: McGowan, Jennifer, et al.
Publicado: (2014)

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy
por: Gupta, Ravindra K., et al.
Publicado: (2014)

Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda
por: Billioux, Alexander, et al.
Publicado: (2015)

Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research
por: Eaton, Ellen F., et al.
Publicado: (2016)

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV
por: Jose, Sophie, et al.
Publicado: (2018)

Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK
por: Asad, H, et al.
Publicado: (2021)

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults
por: Takuva, Simbarashe, et al.
Publicado: (2013)

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Pediatric Response to Second-Line Antiretroviral Therapy in South Africa
por: Zanoni, Brian C., et al.
Publicado: (2012)

Anti-viral Coatings: Protecting Your Health or the Durability of the Item?
Publicado: (2020)

Dynamics and durability of HIV-1 neutralization are determined by viral replication
por: Schommers, Philipp, et al.
Publicado: (2023)

Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second‐line switches in Swaziland
por: Etoori, David, et al.
Publicado: (2018)

Skeletal muscle mitochondrial dysfunction in contemporary antiretroviral therapy: a single cell analysis
por: Hunt, Matthew, et al.
Publicado: (2022)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
por: Stirrup, Oliver T, et al.
Publicado: (2019)

Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes?
por: Moniz, Patricia, et al.
Publicado: (2014)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

High‐risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV‐positive men who have sex with men
por: Pool, ERM, et al.
Publicado: (2018)

Installation of insecticide-treated durable wall lining: evaluation of attachment materials and product durability under field conditions
por: Messenger, Louisa A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_spbtu7ot6tdcm0tu397g99j185